These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2804374)

  • 1. Lymphokine-activated killer cell functions in patients with leukemic B-lymphoproliferative diseases.
    van der Harst D; Brand A; van Luxemburg-Heys SA; Kooy-Winkelaar EM; van Rood JJ
    Blood; 1989 Nov; 74(7):2464-70. PubMed ID: 2804374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia.
    Zhou MX; Findley HW; Davis R; Ragab AH
    Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
    Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
    Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
    Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
    Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors.
    Foa R; Fierro MT; Raspadori D; Bonferroni M; Cardona S; Guarini A; Tos AG; di Celle PF; Cesano A; Matera L
    Blood; 1990 Oct; 76(7):1349-54. PubMed ID: 2207312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.
    Rajaram N; Tatake RJ; Advani SH; Naik SL; Gangal SG
    Cancer Immunol Immunother; 1990; 31(1):44-8. PubMed ID: 2306755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
    Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
    Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
    Margolin KA; Wright C; Forman SJ
    Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct characteristics of lymphokine-activated killer (LAK) cells derived from patients with B-cell chronic lymphocytic leukemia (B-CLL). A factor in B-CLL serum promotes natural killer cell-like LAK cell growth.
    Santiago-Schwarz F; Panagiotopoulos C; Sawitsky A; Rai KR
    Blood; 1990 Oct; 76(7):1355-60. PubMed ID: 2207313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine and natural killing regulation of growth of a hairy cell leukemia-like cell line: the role of interferon-alpha and interleukin-2.
    Reiter Z; Ozes ON; Blatt LM; Taylor MW
    J Immunother (1991); 1992 Jan; 11(1):40-9. PubMed ID: 1734947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
    Subauste CS; Dawson L; Remington JS
    J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
    Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
    Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.
    Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ
    Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.